

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:

10/527,771

Applicant:

Claerebout et al.

Confirmation No.:

5406

U.S.C. 371 Filing Date:

March 11, 2005

International File Date:

September 11, 2003

Group Art Unit:

1645

Examiner:

Gangle, B.

For:

Ostertagia Vaccine

Attorney Docket:

I-2002.015 US

January 27, 2006

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08B. One copy of each of these documents is attached.

This Information Disclosure Statement is being submitted before a first office action on the merits. Accordingly, payment of a fee is not required.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

Appl. No 10/527,771 Information Disclosure Statement Attorney Docket No. I-2002.015 US January 27, 2006

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. 02-2334. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. 02-2334.

Applicants submit that this application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,

Aaron L. Schwartz, PDO Reg. No. 48,181

Attorney for Applicant Patent Department

Intervet Inc.

P.O. Box 318

29160 Intervet Lane

Millsboro, DE 19966

302-933-4034

(302) 934-4305 (fax)

ALS:dap

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information units it contains a valid OMB control number.

Complete if Known

Application Number 10/527,771

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

First Named Inventor

CI AFREDOUT. 44 of

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

First Named Inventor CLAEREBOUT, et al.

Art Unit 1645

Examiner Name B. Gangle

Sheet 1 of 1 Attorney Docket Number I-2002.015 US

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	miss f and f misses manne of the datable (in or it in the LLT), the of the difficient appropriate), title of					
		DE MAERE, V., et al., "Identification of potential protective antigens of Ostertagia ostertagi" Parasitology, October 2002, V 125, p 383-391				
		EMBL Database, March 31, 2001, EMBL Database accession no. AJ310819				
		EMBL Database, May 14, 2001, EMBL Database accession no. BG733986				
		Gencore accession no. AJ310812, March 29, 2001 and August 12, 2001				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.